Press Releases

 
Press Releases
Date Title and Summary View
Mar 31, 2015 PORTLAND, Ore., March 31, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer w...
Mar 26, 2015 PORTLAND, Ore., March 26, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that human leukocyte antigen (HLA) - A24+ or HLA-A26+ women are now e...
Mar 18, 2015 PORTLAND, Ore., March 18, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the closing of its previously announced underwritten public offering ...
Mar 13, 2015 PORTLAND, Ore., March 13, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the pricing of an underwritten public offering of 24,358,974 units at...
Mar 12, 2015 PORTLAND, Ore., March 12, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced it intends to offer shares of its common stock and warrants to purcha...
Mar 5, 2015 Cancer immunotherapy programs - NeuVax™ (nelipepimut-S) and GALE-301 - made significant advancements in 2014 -¬†Achievement of key milestones anticipated in 2015 including completion of enrollment in NeuVax Phase 3 PRESENT trialCommercial strategy validated as revenue continues to increase ahead of second commercial launch -¬†Abstral&#...
Mar 3, 2015 PORTLAND, Ore., March 3, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will...
Feb 19, 2015 PORTLAND, Ore., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that the Company will report its fourth quarter and year end 2014 financial ...
Feb 9, 2015 Key PRESENT trial enrollment milestone achievedOver-enrollment planned with expected completion near the end of Q1 PORTLAND, Ore., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the ...
Feb 5, 2015 PORTLAND, Ore., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that its partner, Orexo AB, has filed a patent infringement lawsuit in Un...
Page:
1
... NextLast
= add release to Briefcase